Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A trial testing the combination of the anti-TIGIT ... advanced unresectable or metastatic non–small cell lung cancer (NSCLC) failed to meet its primary endpoints. Although the SKYSCRAPER-01 ...

Deferring CNS-directed radiation therapy in EGFR-variant and ALK-positive NSCLC with brain metastases improves outcomes ... Looking forward, Pike and his colleagues stated that randomized clinical ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...